Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

被引：0

作者：

H-M Lin

L Castillo

K L Mahon

K Chiam

B Y Lee

Q Nguyen

M J Boyer

M R Stockler

N Pavlakis

G Marx

G Mallesara

H Gurney

S J Clark

A Swarbrick

R J Daly

L G Horvath

机构：

[1] The Kinghorn Cancer Centre/Garvan Institute of Medical Research,Cancer Research Division

[2] Sydney Medical School,Department of Medical Oncology

[3] University of Sydney,undefined

[4] Pharmacogenomic Research for Individualised Medicine (PRIMe) consortium,undefined

[5] Chris O’Brien Lifehouse,undefined

[6] Royal Prince Alfred Hospital,undefined

[7] Medical Oncology,undefined

[8] Concord Repatriation General Hospital,undefined

[9] Concord,undefined

[10] Medical Oncology,undefined

[11] Royal North Shore Hospital,undefined

[12] Northern Haematology and Oncology Group,undefined

[13] Sydney Adventist Hospital,undefined

[14] Calvary Mater Newcastle Hospital,undefined

[15] Westmead Hospital,undefined

[16] St Vincent’s Clinical School,undefined

[17] Faculty of Medicine,undefined

[18] UNSW Australia,undefined

[19] Signalling Network Laboratory,undefined

[20] School of Biomedical Sciences,undefined

[21] Monash University,undefined

来源：

British Journal of Cancer | 2014年 / 110卷

关键词：

circulating microRNAs; chemotherapy; metastatic prostate cancer; biomarkers; docetaxel;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2462 / 2471

页数：9

共 50 条

[21] Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (DRPC)
Reuter, C. W.
Morgan, M. A.
Gruenwald, V.
Fenner, M.
Ivanyi, P.
Ganser, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
[22] CARBOPLATIN PLUS WEEKLY DOCETAXEL AS SALVAGE CHEMOTHERAPY IN DOCETAXEL-RESISTANT AND CASTRATION-RESISTANT PROSTATE CANCER (DRPC)
Reuter, C.
Morgan, M. A.
Fenner, M.
Ivanyi, P.
Ganser, A.
Gruenwald, V.
ANNALS OF ONCOLOGY, 2010, 21 : 301 - 301
[23] Continuing enzalutamide with docetaxel in castration-resistant prostate cancer
Shiota, Masaki
LANCET ONCOLOGY, 2022, 23 (11): : 1345 - 1347
[24] Dasatinib combined with docetaxel for castration-resistant prostate cancer
Araujo, John C.
Mathew, Paul
Armstrong, Andrew J.
Braud, Edward L.
Posadas, Edwin
Lonberg, Mathew
Gallick, Gary E.
Trudel, Geralyn C.
Paliwal, Prashni
Agrawal, Shruti
Logothetis, Christopher J.
CANCER, 2012, 118 (01) : 63 - 71
[25] The roles of microRNAs in the progression of castration-resistant prostate cancer
Satoko Kojima
Yusuke Goto
Yukio Naya
Journal of Human Genetics, 2017, 62 : 25 - 31
[26] DOCETAXEL RETREATMENT IN DOCETAXEL-PRETREATED CASTRATION-RESISTANT PROSTATE CANCER
Di Lorenzo, Giuseppe
Palmieri, Giovannella
Buonerba, Carlo
Marinelli, Alfredo
De Placido, Sabino
Altieri, Vincenzo
Ferro, Matteo
Mariano, Marsicano
Vittorino, Montanaro
Luigi, Castaldo
Antonio, Tesone
Modestino, Tronino
ANTICANCER RESEARCH, 2010, 30 (04) : 1533 - 1533
[27] The roles of microRNAs in the progression of castration-resistant prostate cancer
Kojima, Satoko
Goto, Yusuke
Naya, Yukio
JOURNAL OF HUMAN GENETICS, 2017, 62 (01) : 25 - 31
[28] Chemotherapy options in castration-resistant prostate cancer
Teply, Benjamin A.
Hauke, Ralph J.
INDIAN JOURNAL OF UROLOGY, 2016, 32 (04) : 262 - 270
[29] A prospective multicenter study of intermittent chemotherapy with docetaxel and prednisolone for castration-resistant prostate cancer
Narita, Shintaro
Koie, Takuya
Yamada, Shigeyuki
Orikasa, Kazuhiko
Matsuo, Shigeki
Aoki, Hiroshi
Ishidoya, Shigeto
Hoshi, Senji
Tsuchiya, Norihiko
Ohyama, Chikara
Arai, Yoichi
Habuchi, Tomonori
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (06) : 547 - 553
[30] Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel
Gallardo, Enrique
Angel Arranz, Jose
Pablo Maroto, Jose
Angel Leon, Luis
Bellmunt, Joaquim
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 88 (02) : 357 - 367

← 1 2 3 4 5 →